Tivanisiran, a novel siRNA for the treatment of dry eye disease
Author:
Affiliation:
1. Clínica Universidad de Navarra, Pamplona, Spain
2. Sylentis, Madrid, Spain
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543784.2018.1457647
Reference40 articles.
1. TFOS DEWS II Definition and Classification Report
2. Research in Dry Eye: Report of the Research Subcommittee of the International Dry Eye WorkShop (2007)
3. Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting
4. TFOS DEWS II Epidemiology Report
5. Report of the Inaugural Meeting of the TFOS i2 = initiating innovation Series: Targeting the Unmet Need for Dry Eye Treatment
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Quintessence of currently approved and upcoming treatments for dry eye disease;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-08-31
2. Application of therapeutic nucleic acids and RNA interference to create products for personalised medicine;Biological Products. Prevention, Diagnosis, Treatment;2024-06-14
3. Discovery platforms for RNA therapeutics;British Journal of Pharmacology;2024-05-17
4. Molecular Engineering of Functional SiRNA Agents;ACS Synthetic Biology;2024-05-11
5. TRPV1 in Dry Eye Disease;Frontiers in Bioscience-Landmark;2024-05-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3